We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+10.16%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.87B
AUM Growth
+$199M
Cap. Flow
+$85.5M
Cap. Flow %
2.97%
Top 10 Hldgs %
71.68%
Holding
83
New
11
Increased
14
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$92.5M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$61.6M
3
RCUS icon
Arcus Biosciences
RCUS
+$55.6M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$34.5M
5
ALEC icon
Alector
ALEC
+$21.1M

Top Sells

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$104M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$35.3M
3
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$28.9M
4
NRIX icon
Nurix Therapeutics
NRIX
+$26M
5
KYMR icon
Kymera Therapeutics
KYMR
+$25.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.93%
2 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OVID icon
26
Ovid Therapeutics
OVID
$439M
$20.4M 0.71%
6,082,200
– –
TNGX icon
27
Tango Therapeutics
TNGX
$4.35B
$16.8M 0.58%
1,300,000
+500,000
+63% +$5.99M
BLUE
28
DELISTED
bluebird bio
BLUE
$15.3M 0.53%
+61,954
New +$17.7M
ERAS icon
29
Erasca
ERAS
$6.55B
$14.9M 0.52%
+700,000
New +$14.4M
CNTA
30
DELISTED
Centessa Pharmaceuticals
CNTA
$12.6M 0.44%
754,545
– –
SPRY icon
31
ARS Pharmaceuticals
SPRY
$572M
$11.8M 0.41%
1,184,710
-1,433,326
-55% -$35.3M
ODT
32
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$10.8M 0.38%
3,727,261
+2,896,061
+348% +$9.63M
CRVS icon
33
Corvus Pharmaceuticals
CRVS
$1.09B
$10.1M 0.35%
2,081,077
-1,498,300
-42% -$4.43M
IMVT icon
34
Immunovant
IMVT
$8.23B
$9.91M 0.34%
+1,140,819
New +$10.3M
NUVB.WS
35
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$9.58M 0.33%
963,333
– –
CCCC icon
36
C4 Therapeutics
CCCC
$397M
$8.94M 0.31%
200,000
– –
KRON
37
DELISTED
Kronos Bio
KRON
$8.12M 0.28%
387,357
– –
NGNE icon
38
Neurogene
NGNE
$691M
$6.22M 0.22%
43,031
-74,909
-64% -$11.5M
FLAC
39
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
$5.77M 0.2%
587,615
+387,120
+193% +$3.78M
ACIU icon
40
AC Immune
ACIU
$234M
$5.04M 0.18%
751,251
-1,896,912
-72% -$13.6M
NGM
41
CALL
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$5M 0.17%
+245,000
New +$5.39M
CYCN icon
42
Cyclerion Therapeutics
CYCN
$15.2M
$4.93M 0.17%
80,314
– –
JYAC
43
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.88M 0.17%
500,000
– –
VERV
44
DELISTED
Verve Therapeutics
VERV
$4.7M 0.16%
100,000
– –
KNTE
45
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$4.03M 0.14%
175,000
+150,000
+600% +$3.27M
OBIO icon
46
Orchestra BioMed
OBIO
$229M
$3.96M 0.14%
400,000
– –
PRDS
47
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$3.69M 0.13%
371,014
+221,014
+147% +$2.2M
DYN icon
48
Dyne Therapeutics
DYN
$4.24B
$3.57M 0.12%
215,000
– –
IGMS
49
DELISTED
IGM Biosciences
IGMS
$2.5M 0.09%
38,030
– –
FMTX
50
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$2.09M 0.07%
90,141
-15,497
-15% -$366K
1
2
3 4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2021 Portfolio in Review

As of Q3 2021, EcoR1 Capital held 83 positions worth $2.87B, up 7.4% from $2.68B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital's Q3 2021 filing shows 11 new, 14 increased, 8 reduced and 12 closed positions. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 1,558,749 shares worth $82M. The largest sale was Relay Therapeutics, an estimated $104M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Financials.

  • EcoR1 Capital's largest Q3 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 1,558,749 shares worth $82M.
  • EcoR1 Capital added most to Arcus Biosciences in Q3 2021, an estimated $55.6M increase.
  • EcoR1 Capital's biggest Q3 2021 reduction was Relay Therapeutics, cutting an estimated $104M.
  • EcoR1 Capital fully exited Translate Bio, Inc. Common Stock in Q3 2021, selling an estimated $28.9M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $2.87B portfolio in Q3 2021.
  • EcoR1 Capital opened 11 new positions and closed 12 in Q3 2021.
  • EcoR1 Capital's portfolio value rose 7.4% quarter-over-quarter to $2.87B.

Based on EcoR1 Capital's 13F filing for Q3 2021, filed 15 Nov 2021.